Rein Therapeutics Expands Phase 2 IPF Trial to UK, Enrolls 16 Patients
Summary
Rein Therapeutics is expanding its Phase 2 RENEW clinical trial for LTI-03 in idiopathic pulmonary fibrosis (IPF) into the United Kingdom, with the first patient randomized there. The company has now enrolled 16 of the targeted 120 patients across multiple countries. This operational progress indicates the company is executing on its pipeline development, utilizing the $50 million in dilutive financing secured in May, which had addressed its prior going concern warning. Future updates on patient enrollment and, eventually, clinical data will be key for this small-cap biotech.
At the time of this announcement, RNTX was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.7M. The 52-week trading range was $0.89 to $2.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.